What is the difference between Efpeglenatide and Semaglutide?

Efpeglenatide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly). Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Efpeglenatide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.

Is Efpeglenatide or Semaglutide approved?

Efpeglenatide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Efpeglenatide and Semaglutide?

Peptide Science Daily tracks 5 registered clinical trials for Efpeglenatide (evidence grade B) and 500 for Semaglutide (evidence grade A).

Compound comparison

Efpeglenatide vs Semaglutide

This page sets Efpeglenatide and Semaglutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Efpeglenatide
Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly)
Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism: Efpeglenatide
In plain terms, efpeglenatide mimics the gut hormone GLP-1, prompting the pancreas to release insulin when blood sugar is high, curbing appetite, and slowing stomach emptying.
Semaglutide
In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA): Efpeglenatide
Not approved. Efpeglenatide remains an investigational agent with no FDA marketing authorization.
Semaglutide
Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA): Efpeglenatide
Not authorised. No EMA marketing authorization.
Semaglutide
Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA): Efpeglenatide
Not registered on the ARTG. Investigational only.
Semaglutide
Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA: Efpeglenatide
Not listed as a prohibited substance on the WADA Prohibited List (2026). GLP-1 receptor agonists are not classified as prohibited in or out of competition.
Semaglutide
Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade: Efpeglenatide
B
Semaglutide
A
Tracked clinical trials: Efpeglenatide
5
Semaglutide
500
Full profile: Efpeglenatide
Efpeglenatide profile
Semaglutide
Semaglutide profile

Comparison of Efpeglenatide and Semaglutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Efpeglenatide	Semaglutide
Class	Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly)	Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism	In plain terms, efpeglenatide mimics the gut hormone GLP-1, prompting the pancreas to release insulin when blood sugar is high, curbing appetite, and slowing stomach emptying.	In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA)	Not approved. Efpeglenatide remains an investigational agent with no FDA marketing authorization.	Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA)	Not authorised. No EMA marketing authorization.	Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA)	Not registered on the ARTG. Investigational only.	Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA	Not listed as a prohibited substance on the WADA Prohibited List (2026). GLP-1 receptor agonists are not classified as prohibited in or out of competition.	Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade	B	A
Tracked clinical trials	5	500
Full profile	Efpeglenatide profile	Semaglutide profile

Common questions

What is the difference between Efpeglenatide and Semaglutide?: Efpeglenatide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly). Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Efpeglenatide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.
Is Efpeglenatide or Semaglutide approved?: Efpeglenatide is investigational and is not an approved medicine. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Efpeglenatide and Semaglutide?: Peptide Science Daily tracks 5 registered clinical trials for Efpeglenatide (evidence grade B) and 500 for Semaglutide (evidence grade A).